Claus Jepsen Appointed As President – Global Specialty Of Lupin

Claus Jepsen has been appointed as President, Global Specialty of Lupin Limited, with effect from October 18, 2024.

Claus Jepsen has over 30 years of pharmaceutical industry expertise, with an emphasis on commercial strategy, portfolio management, and launch preparation in Europe, Asia, and the United States. He managed Takeda Pharmaceuticals’ Global Product Strategy for Rare Diseases, collaborating on projects to offer novel therapies to patients with unmet medical needs. Before joining Takeda, he worked at GSK as a country general manager in Asia and global franchise management for immunology, respiratory, and neurology. He established products such as Ellipta in the United States and managed Advair and Seretide in Europe and the United States.